Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Northwestern Medicine scientists have uncovered new insights into how neurofilaments act like Velcro in neurodegenerative ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $341.93, with a high estimate of $500.00 and a low estimate of $280.00. Marking an increase ...

In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...

Given the growing antibiotic resistance crisis, novel ways to target bacterial infections are becoming increasingly important. One potential strategy is to manipulate bacterial genes at the ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint. The results are a landmark for Alnylam which has stuck doggedly ...